(Sharecast News) - Fusion Antibodies reported a narrower first-half loss on Monday, as increased investment in its OptiMAL antibody discovery platform and a series of new contract wins helped improve performance despite lower year-on-year revenue.
The AIM-traded company said it had made "substantial progress" toward the commercial launch of OptiMAL, which...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE